USA NEW
PATENT PENDING!
Stellar news on the home front! Dr.
Katsnelson assigned a new patent to
Kalaco Scientific and on June 19th,
2007, Kalaco officially filed for
the new patent, titled “Multi-channel
Electrostimulation Apparatus and Method.”
Kalaco is very excited about the possibilities
this new technology brings and we
look forward to adding to Kalaco’s
innovation-driven foundation.
The operation of the new apparatus
is based on the modern theory and
knowledge of the mechanisms of pain.
Complementing existing and developing
Nexalin transcranial electro-stimulators,
the multi-channel therapy is designed
to extend the benefit of Kalaco’s
unique family of non-invasive therapies
to a wider group of people, including
patients who might have previously
been contraindicated.
EUROPE
ANXIETY, DEPRESSION, INSOMNIA
(ADI) INDICATIONS APPROVAL
Get ready for Nexalin’s scope
of influence to expand in Europe!
Our notified Body, Intertek ETL SEMKO,
issued an approval to include the
additional indications of Anxiety,
Depression, and Insomnia within our
CE marking. As with the U.S. market,
we plan to add these indications in
Europe, which will significantly extend
our patient base.
GERMANY
WORLD’S FIRST ATTEMPT
AT MEASURING EFFECTS OF TRANSCRANIAL
ELECTRICAL STIMULATION WITH EEG
Groundbreaking news for Kalaco and
medical research! We are in the process
of organizing our participation in
scientific trials in several countries
related to evaluating the use of EEG
measurement of Nexalin treatment.
If successful as speculated, the EEG
may give new means of monitoring the
safety and mechanisms of Nexalin therapy.
In the initial trials, we will participate
with scientists from The University
of Potsdam in Berlin, Germany as well
as Russian institutions. The facilities
and analysis at the University of
Potsdam and the Russian laboratories
for the first tests have been offered
at no charge. Additional research
agreements will follow once the results
of the first tests are known. We welcome
and appreciate the willingness of
these professional facilities to pursue
this novel technique with us. Preliminary
evaluations are currently taking place.
AUSTRALIA
TGA APPROVES THE NEXALIN
DEVICE FOR CE MARK INCLUSION IN RECORD
TIME
Kalaco is thrilled to announce the
considerable strides we’ve taken
in bringing clinics to Australia since
the last newsletter! The Australian
Therapeutic Goods Administration (TGA)
– the equivalent of the United
States FDA – has issued Kalaco
their approval for the Nexalin device
for the relief of Musculoskeletal
Pain as well as the treatment of Anxiety,
Depression, and Insomnia. Our Australian
representative informed us he has
never witnessed such a quick approval
cycle, which is a credit to the thoroughness
of our Technical Documentation and
our Kalaco team. We are eagerly looking
forward to opening clinics in Australia
and continue to progress towards this
goal!
“NEXALIN” TRADEMARK
More good news from the Land Down
Under! Kalaco has received the official
trademark certificate for “Nexalin”
in Australia. This mark will be applied
to Nexalin Advanced Therapy Centers
and the Nexalin device, legally preserving
proprietary status throughout Australia.
|
